Use of routine histopathology and factor VIII‐related antigen/von Willebrand factor immunohistochemistry to differentiate primary hemangiosarcoma of bone from telangiectatic osteosarcoma in 54 dogs

Hemangiosarcoma (HSA) of bone and telangiectatic osteosarcoma (tOSA) can appear similar histologically, but differ in histogenesis (malignant endothelial cells versus osteoblasts), and may warrant different treatments. Immunohistochemistry (IHC) for endothelial cell marker factor VIII‐related antige...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2017-12, Vol.15 (4), p.1232-1239
Main Authors: Giuffrida, M. A., Bacon, N. J., Kamstock, D. A.
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Tumor - metabolism
Bone Neoplasms - diagnosis
Bone Neoplasms - pathology
Bone Neoplasms - veterinary
Diagnosis, Differential
diagnostic tests and procedures
Dog Diseases - diagnosis
Dog Diseases - pathology
Dogs
factor VIII‐related antigen
hemangiosarcoma
Hemangiosarcoma - diagnosis
Hemangiosarcoma - pathology
Hemangiosarcoma - veterinary
immunohistochemistry
osteosarcoma
Osteosarcoma - diagnosis
Osteosarcoma - pathology
Osteosarcoma - veterinary
Retrospective Studies
von Willebrand Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hemangiosarcoma (HSA) of bone and telangiectatic osteosarcoma (tOSA) can appear similar histologically, but differ in histogenesis (malignant endothelial cells versus osteoblasts), and may warrant different treatments. Immunohistochemistry (IHC) for endothelial cell marker factor VIII‐related antigen/von Willebrand factor (FVIII‐RAg/vWF) is a well‐documented ancillary test to confirm HSA diagnoses in soft tissues, but its use in osseous HSA is rarely described. Archived samples of 54 primary appendicular bone tumours previously diagnosed as HSA or tOSA were evaluated using combination routine histopathology (RHP) and IHC. Approximately 20% of tumours were reclassified on the basis of FVIII‐RAg/vWF immunoreactivity, typically from an original diagnosis of tOSA to a reclassified diagnosis of HSA. No sample with tumour osteoid clearly identified on RHP was immunopositive for FVIII‐RAg/vWF. RHP alone was specific but not sensitive for diagnosis of HSA, compared with combination RHP and IHC. Routine histopathological evaluation in combination with FVIII‐RAg/vWF IHC can help differentiate canine primary appendicular HSA from tOSA.
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12259